DocDollars

Paratek Pharmaceuticals, Inc.

PA · United States · Reporting entity ID 100000476817

Total reported 2019–2025
$19.0M
#334 of 2,960 reporting companies — 0% of all reported industry payments
$8.22M in general payments across 111,920 records, plus $10.8M in research funding across 1,026 records.

How it breaks down

General payments $8,216,303
Research funding $10,827,795

Where this comes from

Figures are from the CMS Open Payments “payments grouped by reporting entity” dataset, queried live. Reporting entities are applicable manufacturers and group purchasing organisations required to report under the Sunshine Act.

Summary

Paratek Pharmaceuticals, Inc. reported $19.0M to US doctors and teaching hospitals from 2019 to 2025, ranking #334 of 2,960 reporting companies. 57% of that was research funding and 43% general payments such as consulting, speaking, food and travel. 111,920 general payment records and 1,026 research records were filed.

Common questions about Paratek Pharmaceuticals, Inc.

How much has Paratek Pharmaceuticals, Inc. paid US doctors?

Paratek Pharmaceuticals, Inc. reported $19,044,098 to US physicians and teaching hospitals across the 2019–2025 Open Payments program years: $8,216,303 in general payments, $10,827,795 in research funding.

How does Paratek Pharmaceuticals, Inc. rank among drug and device companies?

It ranks #334 of 2,960 reporting entities by total reported value, about 0% of all industry payments in the dataset.

Does a payment from Paratek Pharmaceuticals, Inc. mean a doctor did something wrong?

No. Open Payments records transfers of value such as speaking fees, consulting, meals, travel and research funding. The data shows the relationship, not its effect on prescribing or care.